Pops Diabetes wins FDA clearance for blood glucose monitoring system

Pops Diabetes Care said this week that the FDA cleared its Pops! one blood glucose monitoring system.

The Minneapolis-based company’s device can be attached directly to the back of a mobile phone and interacts with the user through a coaching app. The Pops! one system also allows users to review their blood glucose trends and share the data with family members and healthcare professionals.

Pops Diabetes Care said it expects to launch the commercialization process in early 2019.

“We are thrilled to have successfully worked with the FDA to clear this novel solution for people with diabetes. POPS! is delivering a simple experience to help people take action to achieve their goals,” CEO Lonny Stormo said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Only a Few More Days to Register for the most anticipated conference of the winter! DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry. Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry. REGISTER NOW Use code LASTCHANCE to save an additional 20%.